About Ajax Therapeutics
Ajax Therapeutics is a Healthcare company based in Cambridge (United States) founded in 2019 by Olli Silvennoinen, and was acquired by Lilly in April 2026. Targeted therapies for hematologic malignancies are developed. It operates on a HealthTech model. Ajax Therapeutics has raised $135 million across 2 funding rounds from investors including Lilly, Schrödinger and Memorial Sloan - Kettering Cancer Center. Ajax Therapeutics offers products and services including AJ1-11095 and AJ1-10502. Its focus areas include Biotechnology and Oncology. Its competitors include Adicet Bio, Orca Bio and Ossium Health; 3 of its 3 listed competitors have raised funding.
Company details
Ajax Therapeutics is engaged in the development of targeted therapies for hematologic cancers, specifically myeloproliferative neoplasms (MPNs) such as myelofibrosis. Advanced computational chemistry and structural biology are utilized throughout the drug discovery process. A new generation of Type II JAK2 inhibitors is being developed to address unmet medical needs by improving therapeutic efficacy and reducing disease persistence. The company operates in the biotechnology sector, partnering with industry leaders like Schrödinger, Inc. to optimize drug-like properties of small molecules. Solutions are aimed at overcoming limitations of existing Type I JAK2 inhibitors through greater precision and selectivity.
- Headquarters Cambridge, United States
- Founders Olli Silvennoinen
- Stage Acquired
- SectorsHealthcare
- Email••••••••
- Website ajaxtherapeutics.com
- Acquired by Lilly (Apr 2026)
Products & Services of Ajax Therapeutics
Ajax Therapeutics offers a comprehensive portfolio of products and services, including AJ1-11095 and AJ1-10502.
A first-in-class Type II JAK2 inhibitor developed.
A next-generation Type II JAK2 inhibitor researched.
Funding Insights of Ajax Therapeutics
Ajax Therapeutics has successfully raised a total of $135M across 2 strategic funding rounds. The most recent funding activity was a Series C round of $95 million completed in May 2024. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $135M
- Total Rounds 2
- Last Round Series C — $95M
- First Round $40M
(Jun 2021)
- Investors Count 10
All 2 funding rounds of Ajax Therapeutics with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| May 2024 | $95M | Series C | – | Goldman Sachs Asset Management | |
| Jun 2021 | $40M | Series B | – | EcoR1 |
10 investors in total: 10 institutional.
Investors in Ajax Therapeutics
Ajax Therapeutics has secured backing from 10 investors, including institutional and venture fund investors. Prominent investors backing the company include Lilly, Schrödinger and Memorial Sloan - Kettering Cancer Center.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Venture capital and private equity firm | vivocapital.com | Palo Alto, United States | ||
Biotech startups are funded by this venture capital firm. | boxercap.com | San Diego, United States | ||
Investment in biotechnology companies is facilitated by this firm. | 2019 | inning1.com | New York, United States | |
Global asset management and investment solutions are provided. | 1989 | gsam.com | London, United Kingdom | |
Traditional pharmaceutical medicines are developed for multiple health fields. | 1876 | lilly.com | United States | |
RA Capital is engaged in evidence-based investing in healthcare and life sciences. | 2004 | racap.com | Boston, United States | |
Manages alternative investments through equity, systematic, macro, and private strategies worldwide. | 2014 | point72.com | Stamford, United States | |
| ecor1cap.com | ||||
Schrödinger is recognized for developing physics-based software platforms for molecular discovery. | 1990 | schrodinger.com | New York, United States | |
Oncology hospitals focused on cancer care and research are maintained. | 1884 | mskcc.org | United States |
Investor details for Ajax Therapeutics
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Ajax Therapeutics
8 people are tracked at Ajax Therapeutics (3 in leadership, 4 in board & advisors, 1 in team).
| Name | Role | Group |
|---|---|---|
Olli Silvennoinen | Co-Founder | Leadership |
Martin Vogelbaum | Interim CEO | Leadership |
Christine Richardson | Senior Director, Program Management | Leadership |
Ramy Farid | Director | Board & advisors |
Scott Platshon | Director | Board & advisors |
Ross Levine | Director | Board & advisors |
Eric S. Fischer | Scientific Advisor | Board & advisors |
Craig E. Masse | SVP, Discovery Research | Team |
Complete people profiles for Ajax Therapeutics
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Timeline of Ajax Therapeutics
4 dated milestones of Ajax Therapeutics across 7 years, from founding to its latest funding, stage changes and deals.
- Founded Ajax Therapeutics is founded.
- Funding First funding round of $40.0M.
- Funding Latest funding round, Series C, of $95.0M.
- Exit Acquired by Lilly.
Competitors of Ajax Therapeutics
Ajax Therapeutics has 3 listed competitors in our database, 3 of them funded. They include Adicet Bio, Orca Bio and Ossium Health.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| adicetbio.com | 2014 | Menlo Park, United States | $51M | 86 | Immune cell therapies for cancer treatment are developed. | |
| orcabio.com | 2016 | Menlo Park, United States | $300M | 66 | Developer of Allogeneic cell therapy for cancer, autoimmune diseases and genetic blood disorders | |
| ossiumhealth.com | 2016 | San Francisco, United States | $125.41M | Ossium Health is focused on bioengineering for improved health. |
Detailed competitors of Ajax Therapeutics
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of Ajax Therapeutics
The website of Ajax Therapeutics (ajaxtherapeutics.com) receives about 2.3K visits a month.
- Monthly visits2.3K
▲ 55.6% vs previous month
Top companies in Hematology
3 companies that operate in the same segment as Ajax Therapeutics (Hematology) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Catheter-based thrombectomy devices for vascular emboli removal are developed. | 2011 | Irvine, California, United States | USD 51.89 M | USD 493.63 M | 696 | |
Small molecules are developed to treat hematologic and musculoskeletal disorders. | 2016 | Lexington, Kentucky, United States | USD 90 M | USD 244.06 M | 169 | |
Developer of Allogeneic cell therapy for cancer, autoimmune diseases and genetic blood disorders | 2016 | Menlo Park, California, United States | USD 300 M | 384 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Ajax Therapeutics
Complete news archive for Ajax Therapeutics
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Ajax Therapeutics
Ajax Therapeutics was founded in 2019 and raised its 1st funding round 2 years after it was founded.
Ajax Therapeutics is headquartered in Cambridge, United States. It is registered at Cambridge, Massachusetts, United States.
Ajax Therapeutics is a funded company, having raised a total of $135M across 2 funding rounds to date. The company's 1st funding round was a Series B of $40M, raised on Jun 2021.
Ajax Therapeutics is engaged in the development of targeted therapies for hematologic cancers, specifically myeloproliferative neoplasms (MPNs) such as myelofibrosis. Advanced computational chemistry and structural biology are utilized throughout the drug discovery process. A new generation of Type II JAK2 inhibitors is being developed to address unmet medical needs by improving therapeutic efficacy and reducing disease persistence. The company operates in the biotechnology sector, partnering with industry leaders like Schrödinger, Inc. to optimize drug-like properties of small molecules. Solutions are aimed at overcoming limitations of existing Type I JAK2 inhibitors through greater precision and selectivity.
Ajax Therapeutics's top competitors include Orca Bio, Ossium Health and Adicet Bio.
Ajax Therapeutics offers AJ1-11095 and AJ1-10502.
Ajax Therapeutics has 10 investors. Key investors include Lilly, Schrödinger, Memorial Sloan - Kettering Cancer Center, RA Capital, and Goldman Sachs Asset Management.
Yes. Ajax Therapeutics was acquired by Lilly in April 2026.